Difference between revisions of "Non-small cell lung cancer, BRAF-mutated"
Jump to navigation
Jump to search
Ryannguyen (talk | contribs) |
m |
||
Line 1: | Line 1: | ||
− | |||
− | |||
− | |||
{| class="wikitable" style="text-align:center; width:50%;" | {| class="wikitable" style="text-align:center; width:50%;" | ||
!colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c"|'''Section editor''' | !colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c"|'''Section editor''' | ||
Line 29: | Line 26: | ||
|} | |} | ||
{| class="wikitable" style="width: 50%; text-align:center;" | {| class="wikitable" style="width: 50%; text-align:center;" | ||
− | !style="width: | + | !style="width: 33%"|Study |
− | !style="width: | + | !style="width: 33%"|Years of study |
+ | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30679-4/fulltext Planchard et al. 2017 (BRF113928-untreated)] | |[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30679-4/fulltext Planchard et al. 2017 (BRF113928-untreated)] | ||
+ | |2014-2015 | ||
|style="background-color:#91cf61"|Phase II (RT) | |style="background-color:#91cf61"|Phase II (RT) | ||
|- | |- | ||
Line 60: | Line 59: | ||
|} | |} | ||
{| class="wikitable" style="width: 50%; text-align:center;" | {| class="wikitable" style="width: 50%; text-align:center;" | ||
− | !style="width: | + | !style="width: 33%"|Study |
− | !style="width: | + | !style="width: 33%"|Years of study |
+ | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993103/ Planchard et al. 2016 (BRF113928-treated)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993103/ Planchard et al. 2016 (BRF113928-treated)] | ||
+ | |2013-2015 | ||
|style="background-color:#91cf61"|Phase II (RT) | |style="background-color:#91cf61"|Phase II (RT) | ||
|- | |- | ||
Line 77: | Line 78: | ||
===References=== | ===References=== | ||
− | # '''BRF113928:''' Planchard D, Besse B, Groen HJ, Souquet PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, Rigas JR, Upalawanna A, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016 Jul;17(7):984-93. Epub 2016 Jun 6. '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993103/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27283860 PubMed] | + | # '''BRF113928:''' Planchard D, Besse B, Groen HJ, Souquet PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, Rigas JR, Upalawanna A, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016 Jul;17(7):984-93. Epub 2016 Jun 6. '''contains verified protocol''' [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30146-2/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993103/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27283860 PubMed] |
[[Category:Non-small cell lung cancer regimens]] | [[Category:Non-small cell lung cancer regimens]] | ||
[[Category:Biomarker-specific pages]] | [[Category:Biomarker-specific pages]] | ||
[[Category:Lung cancers]] | [[Category:Lung cancers]] |
Revision as of 20:24, 16 January 2020
Section editor | |
---|---|
Travis Osterman, DO, MS Vanderbilt University Nashville, TN ![]() |
Note: these are regimens tested in biomarker-specific populations, please see the main NSCLC page for other regimens.
3 regimens on this page
3 variants on this page
|
Advanced or metastatic disease, first-line
Dabrafenib & Trametinib
back to top |
Regimen
FDA-recommended dose |
Study | Years of study | Evidence |
---|---|---|
Planchard et al. 2017 (BRF113928-untreated) | 2014-2015 | Phase II (RT) |
Biomarker Eligibility Criteria
- Biomarker: BRAF V600E
Chemotherapy
- Dabrafenib (Tafinlar) 150 mg PO twice per day
- Trametinib (Mekinist) 2 mg PO once per day
Continued indefinitely
References
- BRF113928: Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, Giannone V, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017 Oct;18(10):1307-1316. Epub 2017 Sep 11. link to original article PubMed
Advanced or metastatic disease, previously treated, BRAF inhibitor-naive
Dabrafenib & Trametinib
back to top |
Regimen
FDA-recommended dose |
Study | Years of study | Evidence |
---|---|---|
Planchard et al. 2016 (BRF113928-treated) | 2013-2015 | Phase II (RT) |
All enrolled patients had progressed on 1 to 3 prior regimens.
Biomarker Eligibility Criteria
- Biomarker: BRAF V600E
Chemotherapy
- Dabrafenib (Tafinlar) 150 mg PO twice per day
- Trametinib (Mekinist) 2 mg PO once per day
Continued indefinitely
References
- BRF113928: Planchard D, Besse B, Groen HJ, Souquet PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, Rigas JR, Upalawanna A, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016 Jul;17(7):984-93. Epub 2016 Jun 6. contains verified protocol link to original article link to PMC article PubMed